Preeti Patel

Dr. Preeti Patel


Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 April 2023 in Life
Verified
Journal Article
Open access
PDF file
LKLakshmi Kumari
Lakshmi Kumari
YCYash Choudhari
Yash Choudhari
PPPreeti Patel
Preeti Patel
GGGhanshyam Das Gupta
Ghanshyam Das Gupta
DCDilpreet singh chahal
Dilpreet singh chahal
BKBalak Das Kurmi
Balak Das Kurmi
A drug’s aqueous solubility is defined as the ability to dissolve in a particular solvent, and it is currently a major hurdle in bringing new drug molecules to the market. According to some estimates, up to 40% of commercialized products and 70–90% of drug candidates in the development stage are poorly soluble, which results in low bioavailability, diminished therapeutic effects, and dosage escalation. Because of this, solubility must be taken into consideration when developing and fabricating pharmaceutical products. To date, a number of approaches have been investigated to address the problem of poor solubility. This review article attempts to summarize several conventional methods utilized to increase the solubility of poorly soluble drugs. These methods include the principles of physical and chemical approaches such as particle size reduction, solid dispersion, supercritical fluid technology, cryogenic technology, inclusion complex formation techniques, and floating granules. It includes structural modification (i.e., prodrug, salt formation, co-crystallization, use of co-solvents, hydrotrophy, polymorphs, amorphous solid dispersions, and pH variation). Various nanotechnological approaches such as liposomes, nanoparticles, dendrimers, micelles, metal organic frameworks, nanogels, nanoemulsions, nanosuspension, carbon nanotubes, and so forth have also been widely investigated for solubility enhancement. All these approaches have brought forward the enhancement of the bioavailability of orally administered drugs by improving the solubility of poorly water-soluble drugs. However, the solubility issues have not been completely resolved, owing to several challenges associated with current approaches, such as reproducibility in large scale production. Considering that there is no universal approach for solving solubility issues, more research is needed to simplify the existing technologies, which could increase the number of commercially available products employing these techniques.

1 March 2024 in Stem Cell Reviews and Reports
Verified
Journal Article
Closed access
PDF file
AVAbhinav Vashishat
Abhinav Vashishat
PPPreeti Patel
Preeti Patel
GGGhanshyam Das Gupta
Ghanshyam Das Gupta
BKBalak Das Kurmi
Balak Das Kurmi

15 November 2023 in Journal of Molecular Structure
Verified
Journal Article
Closed access
PPPreeti Patel
Preeti Patel
RSRuchi Shakya
Ruchi Shakya
VIVishakha
Vishakha
VAVivek Asati
Vivek Asati
BKBalak Das Kurmi
Balak Das Kurmi
HRHarish Rajak
Harish Rajak

1 October 2024 in AAPS PharmSciTech
Verified
Journal Article
Closed access
PDF file
RMRashmi Maurya
Rashmi Maurya
Akash VikalAkash Vikal
Akash Vikal
PPPreeti Patel
Preeti Patel
RNRaj Kumar Narang
Raj Kumar Narang
BKBalak Das Kurmi
Balak Das Kurmi

4 November 2021 in Beni-Suef University Journal of Basic and Applied Sciences
Verified
Journal Article
Open access
PDF file
VPVijay K. Patel
Vijay K. Patel
Ekta ShirbhateEkta Shirbhate
Ekta Shirbhate
PPPreeti Patel
Preeti Patel
RVRavichandran Veerasamy
Ravichandran Veerasamy
PSPrabodh Sharma
Prabodh Sharma
HRHarish Rajak
Harish Rajak
Background: The World Health Organization (WHO) announced the COVID-19 occurrence as a global pandemic in March 2020. The treatment of SARS-CoV-2 patients is based on the experience gained from SARS-CoV and MERS-CoV infection during 2003. There is no clinically accepted therapeutic drug(s) accessible yet for the treatment of COVID-19. Main body: Corticosteroids, i.e., dexamethasone, methylprednisolone, hydrocortisone and prednisone are used alone or in combination for the treatment of moderate, severe and critically infected COVID-19 patients who are hospitalized and require supplemental oxygen as per current management strategies and guidelines for COVID-19 published by the National Institutes of Health. Corticosteroids are recorded in the WHO model list of essential medicines and are easily accessible worldwide at a cheaper cost in multiple formulations and various dosage forms. Corticosteroid can be used in all age group of patients, i.e., children, adult, elderly and during pregnancy or breastfeeding women. Corticosteroids have potent anti-inflammatory and immunosuppressive effects in both primary and secondary immune cells, thereby reducing the generation of proinflammatory cytokines and chemokines and lowering the activation of T cells, monocytes and macrophages. The corticosteroids should not be used in the treatment of non-severe COVID-19 patients because corticosteroids suppress the immune response and reduce the symptoms and associated side effects such as slow recovery, bacterial infections, hypokalemia, mucormycosis and finally increase the chances of death. Conclusion: Intensive research on corticosteroid therapy in COVID-19 treatment is urgently needed to elucidate their mechanisms and importance in contributing toward successful prevention and treatment approaches. Hence, this review emphasizes on recent advancement on corticosteroid therapy for defining their importance in overcoming SARS-CoV-2 pandemic, their mechanism, efficacy and extent of corticosteroids in the treatment of COVID-19 patients.

20 August 2019 in Drug Delivery Letters
Verified
Journal Article
Closed access
PDF file
APAshish K. Parashar
Ashish K. Parashar
PPPreeti Patel
Preeti Patel
AGArun K. Gupta
Arun K. Gupta
NJNeetesh K. Jain
Neetesh K. Jain
BKBalak Das Kurmi
Balak Das Kurmi
Background: The present study was aimed at developing and exploring the use of PEGylated Poly (propyleneimine) dendrimers for the delivery of an anti-diabetic drug, insulin.Methods: For this study, 4.0G PPI dendrimer was synthesized by successive Michael addition and exhaustive amidation reactions, using ethylenediamine as the core and acrylonitrile as the propagating agent. Two different activated PEG moieties were employed for PEGylation of PPI dendrimers. Various physicochemical and physiological parameters UV, IR, NMR, TEM, DSC, drug entrapment, drug release, hemolytic toxicity and blood glucose level studies of both PEGylated and non- PEGylated dendritic systems were determined and compared.Results: PEGylation of PPI dendrimers caused increased solubilization of insulin in the dendritic framework as well as in PEG layers, reduced drug release and hemolytic toxicity as well as increased therapeutic efficacy with reduced side effects of insulin. These systems were found to be suitable for sustained delivery of insulin by in vitro and blood glucose-level studies in albino rats, without producing any significant hematological disturbances.Conclusion: Thus, surface modification of PPI dendrimers with PEG molecules has been found to be a suitable approach to utilize it as a safe and effective nano-carrier for drug delivery.